National Taiwan University College of Medicine, Taiwan
Scientific Tracks Abstracts: Jour Hep Gast dis
Our real world indicated that hepatocellular carcinoma (HCC) is the sixth most frequent malignancy and the second most common cause of cancer-related death. There is a wide variety of therapeutic options for patients with HCC, depending on tumour burden, liver function and performance status. We often used Barcelona Clinic Liver Cancer (BCLC) staging for treatment options. Currently, there are a variety of prediction models for HCC incidence, recurrence, and mortality in different clinical settings (ERASL, CAMPAS...). Here we would like to share the review of HCC prediction models and shared our real world experience with the audience.